Edition:
India

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

19.00USD
20 Jun 2018
Change (% chg)

$-0.05 (-0.26%)
Prev Close
$19.05
Open
$19.00
Day's High
$19.15
Day's Low
$18.95
Volume
109,719
Avg. Vol
164,510
52-wk High
$20.35
52-wk Low
$11.90

Chart for

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment... (more)

Overall

Beta: 1.37
Market Cap(Mil.): $778.29
Shares Outstanding(Mil.): 44.86
Dividend: --
Yield (%): --

Financials

BRIEF-Vanda Pharmaceuticals Inc Reports Qtrly EPS Of $0.06

* VANDA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

03 May 2018

BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt

* U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT

13 Apr 2018

BRIEF-Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule

* VANDA PHARMACEUTICALS - ON MARCH 23, GOT PARAGRAPH IV CERTIFICATION NOTICE LETTER REGARDING ANDA BY TEVA FOR GENERIC VERSION OF 20MG HETLIOZ CAPSULE

26 Mar 2018

BRIEF-Vanda Pharma Prices Public Offering Of Common Stock

* ‍SALE OF 5.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING AT $17.00 PER SHARE​ Source text for Eikon: Further company coverage:

16 Mar 2018

BRIEF-Vanda Pharmaceuticals Inc. Proposes Public Offering Of Common Stock

* VANDA PHARMACEUTICALS INC. PROPOSES PUBLIC OFFERING OF COMMON STOCK

15 Mar 2018

BRIEF-Vanda's Hetlioz Demonstrates Efficacy To Treat Jet Lag Disorder

* HETLIOZ® (TASIMELTEON) DEMONSTRATES EFFICACY TO TREAT JET LAG DISORDER IN AN 8 HOUR PHASE ADVANCE CLINICAL STUDY

05 Mar 2018

BRIEF-Vanda Pharmaceuticals Qtrly Net Loss Per Share $0.04

* VANDA PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS

15 Feb 2018

Competitors

Earnings vs. Estimates